Wharton's jelly vs PRP: composition, preparation and regulatory differences

Two different starting materials behind Wharton's jelly and PRP

PRP is a separate category from donated WJ allografts; this catalog does not provide PRP preparation guidance. Wharton's jelly allograft products begin as donated birth tissue recovered at the time of a scheduled cesarean delivery from a screened, consenting donor, processed by a tissue establishment, and shipped to the clinic as a finished, vialed product with its own lot documentation.

That distinction, autologous versus allogeneic, contributes to differences between the two categories in how each is prepared, what regulatory framework applies, and what documentation a buyer should expect to see before using either one.

How Wharton's jelly and PRP preparation differ

PRP and Wharton's jelly allografts are evaluated as separate procurement categories, each with its own preparation and documentation requirements. This catalog does not provide PRP preparation guidance.

A Wharton's jelly allograft follows a different path before it reaches the clinic. Tissue is recovered by trained, licensed personnel and processed within 48 hours of recovery. Each resulting lot receives a unique identifier, and a sample from that lot goes to a third-party laboratory for sterility testing; the lot is held in quarantine until testing is complete and internal release criteria are met. Depending on the product, the finished allograft is then either cryopreserved at -80 degrees C and shipped overnight on dry ice, or freeze-dried into a shelf-stable, lyophilized format. A clinic receiving either one is receiving a finished product, not something it processes itself.

What's actually in the vial: composition differences

Request composition and preparation documentation for any separate category being evaluated.

Wharton's jelly allografts are derived from the gelatinous extracellular matrix surrounding the umbilical vessels, described in the published literature as rich in hyaluronic acid, collagens, and growth factors. Published analyses of commercial cord-tissue allografts have reported differences in cell counts and protein composition across products tested, which is why a specific lot's certificate of analysis, not category-level literature, is the right reference point for what a given vial contains.

Regulatory posture: autologous use versus the HCT/P framework

Ask counsel to assess PRP requirements separately; do not infer its status from WJ documentation.

Wharton's jelly allografts are allogeneic human tissue regulated under the HCT/P framework at 21 CFR 1271.10. Whether a specific intended use meets all applicable criteria in 21 CFR 1271.10, not simply minimal manipulation or homologous use alone, is a determination for the clinic and its own regulatory counsel to make for that use, not a label either the supplier or the clinic can assign on marketing material alone.

Documentation to request before adding either product to a formulary

The right documentation differs by category, but the underlying ask is the same for both: evidence behind the product, not a product name alone.

Verified accounts can request this documentation directly rather than relying on marketing descriptions. These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.

• For PRP: device clearance documentation, kit lot information, and the draw and spin protocol in writing.
• For Wharton's jelly allografts: the lot certificate of analysis, donor eligibility summary, sterility and release testing results, and chain-of-custody records from recovery through shipment.
• For both: written confirmation of the regulatory classification the supplier is relying on.